SCHEMBL1790221

SCHEMBL1790221

CCC(N)c1ccc(S(=O)(=O)NC(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 3/20 0.53
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
MAPK1 P28482 1/20 0.49
PARG Q86W56 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
CA9 Q16790 1/20 0.43
LMNA P02545 5/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1790218 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL14316697 0.83 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL1793826 0.81 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL1793827 0.81 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL10258693 0.78 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL18703113 0.76 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL13859430 0.75 GAA (0.53) ALDH1A1CYP3A4CYP2C9CA2SLC6A4
SCHEMBL16232128 0.75 SLC6A4 (0.50) CYP3A4LMNAMEN1KMT2ASLC6A4
SCHEMBL16232127 0.75 SLC6A4 (0.50) CYP3A4LMNAMEN1KMT2ASLC6A4
SCHEMBL16232125 0.75 GAA (0.53) ALDH1A1CYP3A4CYP2C9CA2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536187-B2 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2013-09-17 US disclosed
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2011-05-26 US disclosed
WO-2010002998-A1 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, CYP2S1, DPYD ALDH1A1 732/4885SMN1; SMN2 2166/4885MAPT 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.